Effects of YM-14673, a new thyroid-releasing hormone analogue, on neurological deficits in stroke-prone spontaneously hypertensive rats.
The effects of YM-14673, a new thyroid-releasing hormone (TRH) analogue (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on neurological deficits were examined in stroke-prone spontaneously hypertensive rats (SHRSP). The neurological deficits were evaluated for more than 21 days after stroke. Administration of YM-14673 was started the day stroke was observed and repeated daily for 3 weeks. YM-14673 (0.1 and 0.3 mg/kg i.p.) improved the neurological deficits and reduced mortality. These results demonstrate that YM-14673 mitigates cerebral ischemic changes in SHRSP.
Yamamoto
M
M
Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.
Sudoh
K
K
Sasamata
M
M
D000818:Animals; D001384:Azetidines / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000235:genetics / Q000503:physiopathology*; D004151:Dipeptides / Q000494:pharmacology*; D008297:Male; D009422:Nervous System Diseases / Q000209:etiology / Q000503:physiopathology*; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D011918:Rats, Inbred SHR
D001384:Azetidines; D004151:Dipeptides; C054995:azetirelin